Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT07257822
Active, not recruiting Not applicable

The Digital Diabetes Patient Reminder (DIPAR) Tool For Adults With Type 2 Diabetes

NCT07257822 · tracked via the Priya Life Science Belgium tracker
Sponsor
KU Leuven
Phase
Not applicable
Started
2025-10-06
Last updated
2026-02-19

Condition(s) studied

Type 2 Diabetes Mellitus (T2DM)

Investigational drug(s) / intervention(s)

Digital Diabetes Patient Reminder ToolStandard of Care treatment and follow-up

Digital Diabetes Patient Reminder Tool: \- Reminder function: participants will receive reminders that align with the minimal follow-up requirements in Belgium, when the HbA1c and albuminuria measurements are overdue o Notification schedule: HbA1c: First reminder after 7 months without a measurement; second reminder 4 weeks later if still overdue. Albuminuria: First reminder after 13 months without a measurement; second reminder 4 weeks later if still overdue. \- Consultation dashboard: this feature will allow the display selected diabetes clinical parameters in a visual and colorful display. The selected parameters are: HbA1c (%), LDL-C (mg/dl), systolic and diastolic blood pressure (mmHg), albuminuria (mg/gACR), eGFR (ml/min/1.73m2) and BMI (weight/lenght2). Furthermore, participants will be provided with a questionnaire that targets selfcare behaviors and are required to complete this before consultations with their diabetes-specialist or general practitioner.

Standard of Care treatment and follow-up: This allows for the control to group to receive only their routine consultation and follow-up care as provided by their diabetes specialist.

Study summary

Digital health tools may present an opportunity to address these challenges by enhancing care delivery, improving patient engagement, and facilitating better disease management for chronic diseases such as type 2 diabetes mellitus (T2DM). This primary objective of this randomized controlled trial is to evaluate whether the Diabetes Digital Patient Reminder (DIPAR), embedded in patient portal, can increase the proportion of T2DM patients who have their albuminuria measured at least once annually by either a general practitioner (GP) or a diabetes specialist, as documented in their hospital medical records (EMD), thereby reflecting active monitoring of diabetes-related parameters.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures; * Adults 18 years or older; * Treated and followed-up for Type 2 diabetes at the department of endocrinology at the participating hospitals; * Patients with (the ability to access) the MyNexuz patient portal; * Patients with the ability to understand Dutch, French or English. Exclusion Criteria: * Participant is pregnant or hospitalized at the time of recruitment; * Are unable to use a mobile phone because of mental or cognitive impairment; * Deemed ineligible by the treating physicians.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Regional Hospital of Leuven Leuven Flemish Brabant
University Hospital of UZ Leuven Leuven Flemish Brabant

More KU Leuven trials in Belgium

The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project). Starting soon
Cerebellar Research in Ultrasound Stimulation Starting soon
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types Recruiting
Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome) Recruiting
Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate. Recruiting

Other trials for the same condition

Polyphenol Metabotypes in People With Diabetes Type 2 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07257822 on ClinicalTrials.gov ↗ ← All trials in Belgium